Q-omics provides the consensus-scored CMAHP profile across patient tissues and cancer cell-line models. CMAHP expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CMAHP is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CMAHP RNA expression shows 25,518 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KICH, and LSCC as cancer lineages where CMAHP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMAHP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMAHP survival associations across molecular data types. CMAHP RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMAHP RNA expression–survival associations across cancer types. High CMAHP expression shows unfavorable associations in LGG, but favorable associations in SKCM, HNSC, LUAD, UCS and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CMAHP RNA expression.
This table summarizes CMAHP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CMAHP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMAHP shows lower tumor expression in KICH, COAD, BLCA, THCA, LUAD and LUSC. The KICH box plot shows higher CMAHP RNA expression in normal versus tumor tissue (log2 FC = −2.368, t-test p < 0.001).
This table shows molecular features associated with CMAHP in patient tissues and cancer cell lines. In patient samples, CMAHP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
